Fast Five Quiz: Exudative (Wet) Age-Related Macular Degeneration (AMD)

F. Ryan Prall, MD

September 24, 2021

Anti-VEGF agents are considered to have equivalent efficacy and safety profiles in AMD treatment. These agents have demonstrated improved visual and anatomic outcomes compared with other therapies. However, consensus has not been reached regarding the ideal treatment intervals with anti-VEGF agents.

Learn more about the use of antiangiogenic agents for management of wet AMD.

Editor's Recommendations

Exudative (Wet) Age-Related Macular Degeneration (AMD)

1 2 3 4 5 6

Next Section

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: F. Ryan Prall. Fast Five Quiz: Exudative (Wet) Age-Related Macular Degeneration (AMD) - Medscape - Sep 24, 2021.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

Return to Article

Post as:

processing....

Fast Five Quiz: Exudative (Wet) Age-Related Macular Degeneration (AMD)

Tables

Authors and Disclosures

Authors and Disclosures

Author(s)

F. Ryan Prall, MD

Comments

Most Popular Articles

Email This

Feedback